503058-51-3

Basic information

• Product Name: 4-Chloro-2-chloroMethyl-3-Methoxypyridine, HCl
• Synonyms: 4-Chloro-2-chloroMethyl-3-Methoxypyridine, HCl;4-Chloro-3-methoxypicolinyl chloride hydrochloride;KPQDKAMSAVONFC-UHFFFAOYSA-N
• CAS NO: 503058-51-3
• Molecular Formula: C7H8Cl3NO
• Molecular Weight: 228.50352
• Mol File: 503058-51-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 286.3 °C at 760 mmHg
• Flash Point: 126.9 °C
• Appearance: /
• CAS DataBase Reference: 4-Chloro-2-chloroMethyl-3-Methoxypyridine, HCl(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-2-chloroMethyl-3-Methoxypyridine, HCl(503058-51-3)
• EPA Substance Registry System: 4-Chloro-2-chloroMethyl-3-Methoxypyridine, HCl(503058-51-3)

Safety Data

• Hazardous Substances Data: 503058-51-3(Hazardous Substances Data)

Usage

Uses

4-Chloro-2-chloromethyl-3-methoxypyridine Hydrochloride is a useful reactant in preparation of symmetric bis0benzimidazole derivatives for inhibition of gastric acid secretion.

Upstream product

• 170621-85-9 4-Chloro-2-hydroxymethyl-3-methoxypyridine 

Downstream Products

• 368890-20-4 (5-difluoromethoxy)-2-[(4-chloro-3-methoxy-2-pyridinyl)methyl]thio-1H-benzimidazole 

Relevant articles and documents

ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS

The invention relates to benzimidazoles of Formula (1) and to pharmaceutical compositions comprising these compounds, further to intermediates of Formula (2 and 3).

Benzimidazole derivatives

A benzimidazole derivative of formula (1): (wherein R represents a hydrogen atom or a methoxy group, and n is 0 or 1) or a salt thereof; and a medicament containing the same. The compounds of the present invention, due to minimized difference in therapeutic effect between subjects, which difference would otherwise be derived from different CYP2C19 activity from subject to subject, ensure that all patients can enjoy proper therapeutic effects at the same dose of the drug. Also, the compounds of the invention have low risk of drug interaction caused by induction of CYP1A family member enzymes, as well as low risk of development of cancer, and thus is useful as a remedy for peptic ulcer, reliably providing therapeutic effects with safety.